ArticleNeuro-oncology2025

The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma.

Matthew McCord et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.